NCT06198517 Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
| NCT ID | NCT06198517 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yi Zhang |
| Condition | Moxibustion |
| Study Type | INTERVENTIONAL |
| Enrollment | 266 participants |
| Start Date | 2024-03-21 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 266 participants in total. It began in 2024-03-21 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The control group was treated conventionally, and the experimental group increased moxibustion of Zhongji, Guanyuan and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation. Urine routine tests were performed at the time of admission, +1d, and +14d, and urine BK virus, JC virus, and adenovirus were tested at four time points, namely, +1d, +14 days, onset of hematuria symptoms, and remission of HC, respectively; routine urine tests were performed once every 7 days for all patients within 100days. For patients with Hemorrhagic cystitis (HC), daily severity grading, pain scoring, cystitis symptom scoring, use of antispasmodic and analgesic medications, and major TCM evidence were recorded with the aim of evaluating the efficacy of moxibustion in the prevention of HC in this patient population.
Eligibility Criteria
Inclusion Criteria: 1. Patients are fully aware of the study, participate voluntarily and sign the informed consent form (ICF); 2. Age: 14-60 years; 3. Patients with pernicious blood diseases undergoing allo-HSCT using the MAC protocol or patients with severe aplastic anemia (Severe aplastic anemia; severeaplasticanimin, SAA) undergoing allo-HSCT; Exclusion Criteria: 1. refuse to participate in this clinical study; 2. The corresponding skin at the moxibustion site is broken or sensitive; 3. allo-HSCT pretreated with the RIC program;
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06198517 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 60 Years, studying Moxibustion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06198517 currently recruiting?
Yes, NCT06198517 is actively recruiting participants. Contact the research team at zy188603@163.com for enrollment information.
Where is the NCT06198517 trial being conducted?
This trial is being conducted at Zhengzhou, China, Wuhan, China, Kunming, China, Hangzhou, China.
Who is sponsoring the NCT06198517 clinical trial?
NCT06198517 is sponsored by Yi Zhang. The trial plans to enroll 266 participants.